| Contrave (naltrexone/bupropion) / Currax |
2021-002145-15: Using Mysimba, weight loss medication, in patients who previously underwent a stomach altering operation, because of being extremely overweight, and are now regaining weight again. |
|
|
| Not yet recruiting | 4 | 116 | Europe | naltrexone/bupropion, Tablet, Mysimba 8 mg/90 mg prolonged-release tablets | Nederlandse Obesitas Kliniek, Goodlife | Weight regain post bariatric surgery, Weight regain after stomach altering weight loss surgery because of being overweight, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
COR-WR, NCT04587843: A Trial Evaluating the Effectiveness of Contrave in Patients Who Have Weight Recidivism Following Bariatric Surgery |
|
|
| Active, not recruiting | 4 | 18 | Canada | Contrave 8Mg-90Mg Extended-Release Tablet, naltrexone HCl/bupropion HCl, Placebo, Inactive | St. Joseph's Healthcare Hamilton, Bausch Health, Canada Inc. | Obesity | 12/23 | 12/23 | | |
COR-WM, NCT04589130: Evaluating Contrave for Weight Maintenance in Adults With BMI >= 27 Kg/m2, After 6 Month Behaviour Modification Program. |
|
|
| Active, not recruiting | 4 | 89 | Canada | Contrave 8Mg-90Mg Extended-Release Tablet, naltrexone HCl/bupropion HCl, Placebo, Inactive | St. Joseph's Healthcare Hamilton, Bausch Health, Canada Inc. | Obesity | 12/23 | 12/23 | | |
NCT05579249: A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America |
|
|
| Active, not recruiting | 4 | 500 | US | Semaglutide, Wegovy, Orlistat, Xenical, Phentermine/Topiramate, Qsymia, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda | Novo Nordisk A/S | Obesity | 11/24 | 02/25 | | |
NCT04902625: Use of Mysimba in Patients With Weight Regain After Bariatric Surgery |
|
|
| Recruiting | 4 | 116 | Europe | Naltrexone-Bupropion Combination, Mysimba, Contrave | Zuyderland Medisch Centrum, Nederlandse Obesitas Kliniek | Obesity, Morbid, Bariatric Surgery Candidate, Medication Persistence | 03/25 | 03/25 | | |
NCT05919797: Weight Loss Study: Genetics and Response to Naltrexone/Bupropion |
|
|
| Recruiting | 4 | 120 | US | Naltrexone-Bupropion Combination, Contrave | Columbia University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity | 06/27 | 06/27 | | |
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) |
|
|
| Recruiting | 4 | 8600 | US | Naltrexone-Bupropion (NB) Combination, Placebo | Currax Pharmaceuticals | Obesity | 01/29 | 07/29 | | |
NCT03045341: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment |
|
|
| Completed | 2/3 | 136 | US | NB medication (Naltrexone Bupropion combination), Contrave, Behavioral Weight Loss (BWL) counseling, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Binge-eating Disorder, Obesity | 07/21 | 12/22 | | |
NCT03063606: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment |
|
|
| Completed | 2/3 | 31 | US | Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment), Contrave | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Binge-Eating Disorder, Obesity | 12/21 | 12/22 | | |
NCT03047005: Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy |
|
|
| Completed | 2/3 | 68 | US | NB medication (Naltrexone Bupropion combination), Contrave, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Binge-Eating Disorder, Obesity | 12/21 | 12/22 | | |
NCT03539900: Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder |
|
|
| Completed | 2/3 | 89 | US | Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination, Contrave, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Binge-Eating Disorder | 04/22 | 03/23 | | |
NCT04599478: Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) |
|
|
| Recruiting | 2/3 | 160 | US | Naltrexone and Bupropion medication, Contrave, Behavioral Weight Loss, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Loss-of-control Eating, Obesity/Overweight | 01/26 | 01/27 | | |
NCT04605081: Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) |
|
|
| Enrolling by invitation | 2/3 | 100 | US | Naltrexone and Bupropion (NB) medication, Contrave, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Loss-of-Control Eating, Obesity/Overweight | 05/27 | 05/27 | | |
| Completed | 2 | 55 | US | Contrave, Naltrexone/Bupropion, Behavioral Weight Loss | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, American Institute for Cancer Research, Breast Cancer Research Foundation, Hopkins-WellSpan Cancer Research Fund | Breast Cancer, Overweight or Obesity | 01/24 | 01/24 | | |
| Withdrawn | 1 | 60 | US | Contrave 8Mg-90Mg Extended-Release Tablet, Naltrexone HCl/Bupropion HCl 8 Mg-90 Mg, Bupropion, Wellbutrin, Zyban | University of California, Los Angeles | Stimulant Use, Relapse, Cognitive Function, ADHD | 01/25 | 01/25 | | |
| Completed | N/A | 43324 | US | | Currax Pharmaceuticals | Obesity | 10/22 | 10/22 | | |
| Recruiting | N/A | 24 | US | Semaglutide, Glucagon-like peptide-1 receptor (GLP1-R) agonist, Wegovy, Phentermine-Topiramate combination, Qsymia, Phentermine, Lomaira, Adipex-P, Tirzepatide, Mounjaro, Zepbound, GIP/GLP-1 RA, Topiramate, Topamax, Trokendi XR, Qudexy XR, Diethylpropion, Tenuate, Diethylcathinone, Naltrexone/Bupropion, Contrave, Liraglutide, Saxenda, Victoza | Louisiana State University Health Sciences Center in New Orleans, Tulane University, Pennington Biomedical Research Center, Ochsner Health System | Obesity | 12/24 | 03/25 | | |
| Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories |
QUARTZ, NCT06276361: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia |
|
|
| Recruiting | 1 | 100 | RoW | Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Deltoids | Rovi Pharmaceuticals Laboratories | Schizophrenia | 05/26 | 05/26 | | |
RESHAPE, NCT05480046: Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse |
|
|
| Recruiting | N/A | 1200 | Europe | Risperidone ISM, OKEDI® | Rovi Pharmaceuticals Laboratories | Schizophrenia | 12/24 | 12/24 | | |
| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories |
2017-000213-23: Dual treatment for patients with chronic kidney disease, high blood pressure and diabetes. Combinatiebehandeling voor chronische nierschade bij hoge bloeddruk en diabetes. |
|
|
| Ongoing | 4 | 31 | Europe | Tablet, Entresto, Valsartan | | Chronic kidney disease with concurrent hypertension and diabetes. Chronische nierinsufficientie bij hypertensie en diabetes mellitus., Chonic kidney disease with concurrent high blood pressure and diabetes. Chronische nierschade bij hoge bloeddruk en suikerziekte., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
2017-002914-30: LCZ696 in heart failure patients: effect on left ventricular remodeling and fibrosis assessed by novel heart failure biomarkers and cardiac magnetic resonance LCZ696 en pacientes con insuficiencia cardiaca: efecto en el remodelado ventricular izquierdo y fibrosis evaluados mediante nuevos biomarcadores de insuficiencia cardíaca y resonancia magnética cardíaca. |
|
|
| Ongoing | 4 | 68 | Europe | Entresto, LCZ696, Tablet, Entresto | FIMABIS, FIMABIS | Chronic heart failure NYHA class II-IV with reduced ejection fraction (EF =< 40%) and elevated NT-proBNP ≥ 600 pg/mL, but 400 pg/mL if hospitalized for heart failure within 12 months Insuficiencia cardiaca crónica NYHA clase II-IV con fracción de eyección reducida (EF = <40%) y elevada NT-proBNP ≥ 600 pg / mL, o NT-proBNP ≥ 400 pg / mL si el paciente ha sido hospitalizado por insuficiencia cardíaca en los últimos 12 meses., Chronic heart failure Insuficiencia cardíaca crónica, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2000030460: Clinical study for the efficacy and safety of Sacubitril/Valsartan in the treatment of acute decompensated heart failure |
|
|
| Completed | 4 | 120 | | sacubitril/valsartan | Department of Cardiology, The First Affiliated Hospital of Harbin Medical University; Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, National Science Foundation of China (81270252 and 81700305). | acute decompensated heart failure | | | | |
ChiCTR2100046851: Clinical study on the efficacy and safety of Sacubitril/ Valsartan in patients with acute decompensation of chronic heart failure |
|
|
| Completed | 4 | 125 | | sacubitril/valsartan ;ACEI/ARB | The First Affiliated Hospital of Harbin Medical University; The First Affiliated Hospital of Harbin Medical University, National Science Foundation of China (81270252 and 81700305). | heart failure | | | | |
ChiCTR1800018905: Efficacy and safety of sacubitril/valsartan (LCZ696) in Chinese patients with Ischemic cardiomyopathy |
|
|
| Recruiting | 4 | 1500 | | Benazepril hydrochloride group ;Benazepril hydrochloride | The First affiliated hospital of Zhengzhou University; The First affiliated hospital of Zhengzhou University, Natural Science Foundation of China (81600290) | ischemic cardiomyopathy | | | | |
ChiCTR1800020423: Efficacy and safety of sacubitril/valsartan (LCZ696) in the treatment of Chinese patients with Advanced HF |
|
|
| Not yet recruiting | 4 | 200 | | Benazepril hydrochloride group ;sacubitril/valsartan(LCZ696) group | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, self-raised | Advanced HF | | | | |
ChiCTR1800014308: Effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and renal dysfunction |
|
|
| Not yet recruiting | 4 | 600 | | LCZ696 | Tianjin First Central Hospital; Tianjin First Central Hospital, Tianjin science and technology commission | heart failure | | | | |
ChiCTR1800015826: A real-world clinical observation: the quality of life and safety of sacubitril/valsartan in chronic Heart Failure patients with reduced ejection fraction |
|
|
| Recruiting | 4 | 300 | | sacubitril/valsartan | Second Affiliated Hospital of Nanchang University; Second Affiliated Hospital of Nanchang University, Ministry of Science and Technology | Heart failure | | | | |
ChiCTR1800015649: New active element (rhBNP) sequential sand kubah song/valsartan (LCZ696) in the treatment of acute heart failure study |
|
|
| Not yet recruiting | 4 | 300 | | base treament ;rhBNP combine base treatment ;rhBNP combine LCZ696 | Tianjin Union Medical Center; Tianjin Union Medical Center, self-raised | acute heart failure | | | | |
ChiCTR2000034257: A long-term follow-up study of recurrence after atrial fibrillation ablation with Sacubitril Valsartan treatment |
|
|
| Recruiting | 4 | 212 | | Sacubitril Valsartan ;Valsartan | First Affiliated Hospital of Zhejiang University; First Affiliated Hospital of Zhejiang University, Establishment of atrial fibrillation database, information management and precision medical strategy | atrial fibrillation | | | | |
ChiCTR1900023326: The Effects of Sacubitril/Valsartan on LV Remodelling and Fibrosis in Patients with HFrEF after AMI |
|
|
| Not yet recruiting | 4 | 40 | | Sacubitril/Valsartan ;perindopril | The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University, None | Heart failure | | | | |
ChiCTR2000039291: The effects of Sacubitril/Valsartan and Amlodipine on ventricular remodeling in hypertensive patients with left ventricular hypertrophy: a prospective, randomized controlled clinical study |
|
|
| Recruiting | 4 | 44 | | Sacubitril/Valsartan ;Amlodipine | Zhongda Hospital Affiliated to Southeast University; Zhongda Hospital Affiliated to Southeast University, Self-raising | Hpertension | | | | |
ChiCTR2000040750: Application of sarcubatroxtan in the treatment of chronic heart failure in Hemodialysis patients: a prospective open label single center cohort study |
|
|
| Recruiting | 4 | 20 | | Sacubitril/valsartan | Blood Purification Center of Peking University International Hospital; Peking University International Hospital, self-financing | Heart failure in hemodialysis patients | | | | |
ChiCTR1900028053: Efficacy and safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction: a Multi-Centre, Assessor-Blinded, Cohort Study |
|
|
| Not yet recruiting | 4 | 500 | | Sacubitril/Valsartan group ;ACEI/ARB group | Chongqing Kanghua Zhonglian Cardiovascular Hospital; Chongqing Kanghua Zhonglian Cardiovascular Hospital, Chongqing Kanghua Zhonglian Cardiovascular Hospital supports related research funds | Heart failure | | | | |
ChiCTR2100043544: Antihypertensive effect of sacubitril/valsartan in peritoneal dialysis patients complicated with refractory hypertension |
|
|
| Recruiting | 4 | 60 | | sacubitril/valsartan | Department of Nephrology, General Hospital of Ningxia Medical University; Ningxia Medical University General Hospital, Funding for other scientific research projects | Refractory hypertension in maintenance peritoneal dialysis | | | | |
| Recruiting | 4 | 80 | US | Furosemide, Lasix, Torsemide, Demadex, Bumetanide, Bumex, sacubitril/valsartan, Entresto, Hydralazine, Apresoline, Isosorbide Dinitrate, Dilatrate, Isordil | Heart Center Research, LLC, Boston Scientific Corporation | Heart Failure, Congestive | 12/25 | 12/26 | | |
ChiCTR1900026530: Clinical study for the effects of sacubitril/valsartan on sST2 and Gal-3 in patients with chronic heart failure |
|
|
| Not yet recruiting | 4 | 200 | | sacubitril/valsartan ;Not stated | Yongchuan Hospital Of Chongqing Medical University; Yongchuan Hospital Of Chongqing Medical University, Chongqing municipal health and health commission, Yongchuan Hospital Of Chongqing Medical University | Chronic heart failure | | | | |
ChiCTR2000039561: Effect of Sacubitril/Valsartan on cardiac function and residual renal function in peritoneal dialysis patients with heart failure |
|
|
| Recruiting | 4 | 40 | | sacubitril/valsartan ;valsartan | Department of Nephrology, Affiliated Hospital of Nantong University; Affiliated Hospital of Nantong University, Self-financing | Chronic Kidney Disease | | | | |
ChiCTR2000040617: A prospective randomized controlled and exploratory clinical study on Sacubitril-Valsartan protecting residual kidney function in patients with maintenance peritoneal dialysis |
|
|
| Not yet recruiting | 4 | 72 | | Standard treatment of peritoneal dialysis+ oral taken Sacubitril-Valsartan ;Standard treatment of peritoneal dialysis | The third xiangya hospital of Central South University; The third xiangya hospital of Central South University, Self-financing | End-stage renal disease | | | | |
ChiCTR2100042755: Effect of Sacubitril/valsartan sodium on cardiac function in patients with preserved ejection fraction after acute myocardial infarction |
|
|
| Recruiting | 4 | 200 | | Conventional drugs ;Sacubitril/valsartan | Jiangmen Central Hospital; Jiangmen Central Hospital, self-raised | heart failure | | | | |
| Recruiting | 4 | 50 | US | Sacubitril-Valsartan, Entresto, Usual care (standard-of-care) arm, Oral Vasodilator | The Cleveland Clinic | Stage D Heart Failure | 03/22 | 12/22 | | |
ChiCTR2100048161: A multicenter, randomized, open-label study on the effectiveness of sacubitrilvalsartan in patients with hypertension and elevated natriuretic peptides |
|
|
| Not yet recruiting | 4 | 300 | | Conventional treatment and sacubitrilvalsartan ;Conventional treatment and antihypertensive drugs | Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Government funding | Hypertension | | | | |
EMRP18106N, NCT04217135: The Prognostic Impact of Using High-dose Hydralazine in Severe Systolic Heart Failure With Hemodynamically Significant Mitral Regurgitation |
|
|
| Recruiting | 4 | 400 | RoW | evidence-based medications vs. high-dose hydralazine + evidence-based medications | Kaohsiung Veterans General Hospital., E-DA Hospital | Systolic Heart Failure Stage D (Disorder), Mitral Regurgitation | 07/22 | 07/22 | | |
ChiCTR2200055924: Study on the influencing factors of sacubitril/valsartan clearance in peritoneal dialysis |
|
|
| Recruiting | 4 | 40 | | NA | West China Hospital of Sichuan University; West China Hospital, Sichuan University, Sichuan Science and Technology Program (2020YJ0046) | Chronic Kidney Diseases | | | | |
ChiCTR2300073399: Comparison of the Antihypertensive Efficacy and Safety of Sacubitril and Valsartan in Patients with Mild to Moderate Essential Hypertension and Aortic Dissection |
|
|
| Completed | 4 | 320 | | Valsartan ;Sacubitril-valsartan | Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, Nuochuang Hypertension Research and Innovation Fund | aortic dissection | | | | |
NCT05060588: Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction |
|
|
| Not yet recruiting | 4 | 200 | RoW | Sacubitril/Valsartan 49/51mg/Tab, Sacubitril/Valsartan Group, Valsartan 80mg/Tab, Valsartan Group | Qingdao Central Hospital | Myocardial Infarction, Hypertension | 10/22 | 02/23 | | |
2020-006072-32: Association between sacubitril/valsartan use and pulomonary resistance in patients with heart failure with reduced ejection fraction. Związek między zastosowaniem sakubitrylu/walsartanu a leczeniem nadciśnienia płucnego wtórnego u pacjentów z niewydolnością serca z obniżoną frakcją wyrzutową. |
|
|
| Not yet recruiting | 4 | 260 | Europe | Film-coated tablet, ENTRESTO 24mg/26mg caoted tablets, ENALAPRIL 2.5mg tablets | Heliodor Święcicki Clinical Hospital of the Poznań University of Medical Sciences, Medical Research Agency | Heart Failure with reduced ejection fraction., Heart Failure with reduced ejection fraction., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Not yet recruiting | 4 | 60 | RoW | Sacubitril / Valsartan Oral Tablet, CMR examination | RenJi Hospital | Myocardial Injury, Connective Tissue Diseases | 11/22 | 11/22 | | |
NCT04572724: The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value |
|
|
| Recruiting | 4 | 120 | RoW | Sacubitril / Valsartan Oral Tablet, RAS Inhibitors | Shenzhen Second People's Hospital | Peritoneal Dialysis Complication, Hemodialysis Complication, Heart Failure | 11/22 | 06/23 | | |
| Active, not recruiting | 4 | 60 | Europe, RoW | Sacubitril-Valsartan, Standard of care | University of Zagreb | Heart Failure | 02/25 | 02/25 | | |
ChiCTR2000035387: A prospective, randomized, controlled trial for the efficacy and safety of improving left ventricular remodeling in combined use of sacubitril-valsartan and dapagliflozin compared to RAAS inhibitors in very elderly patients with acute myocardial infarction at the early stage of hospitalization |
|
|
| Not yet recruiting | 4 | 150 | | sacubitril-valsartan and dapagliflozin ;RAAS inhibitors | HuaDong Hospital; HuaDong Hospital, The second round of The Three-year Action Plan for Promoting Clinical Skills and Clinical Innovation in Municipal Hospitals of Shanghai Shenkang Hospital Development Center | acute myocardial infarction | | | | |
ChiCTR2000039648: Comparison of the effects of sacubitril/valsartan and RAAS blockers on the reverse remodeling of heart failure induced by myocardial infarction |
|
|
| Recruiting | 4 | 120 | | sacubitril/valsartan ;ACEI | Department of Cardiology, Affiliated Hospital of Xuzhou Medical University; Affiliated Hospital of Xuzhou Medical University, Jiangsu Postgraduates Research and innovation practice project funds | Heart failure | | | | |
ChiCTR2100042337: To evaluate the application of Sacubitril Valsartan Sodium Tablets (LCZ696) in the early stage of acute myocardial infarction |
|
|
| Recruiting | 4 | 494 | | Sacubitril/Valsartan ;Valsartan | The Seventh People's Hospital of Zhengzhou; Level of the institution：, Hospital self-raised | acute myocardial infarction | | | | |
ChiCTR2100054606: Study on the antihypertensive efficacy and safety of sacubitril and valsartan sodium tablets in the morning and evening |
|
|
| Not yet recruiting | 4 | 150 | | Morning sacubitril and valsartan sodium tablets ;Sacubitril and Valsartan Sodium Tablets before going to bed ;Sacubitril valsartan sodium tablet twice daily group | Guangdong Provincial People's Hospital; Guangdong Provincial People's Hospital, China Cardiovascular Health Alliance-Nuo Chuangxin Hypertension Research and Innovation Fund | hypertension | | | | |
ChiCTR2200066428: Effect of sacubitril/valsartan in lowering blood pressure and its effect on glycolipid metabolism in diabetes mellitus patients with primary hypertension: a randomized controlled study |
|
|
| Recruiting | 4 | 138 | | treament of olmesartan for 8 weeks ;treament of sacubitril/valsarta for 8 weeks | Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College; Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, XinXin Heart （SIP）Foundation | Primary hypertension and diabetes mellitus | | | | |
NCT05243199: Sacubitril/Valsartan for CKD5 Stage Dialysis Patients |
|
|
| Completed | 4 | 330 | RoW | Sacubitril/Valsartan, ARNI, Irbesartan, ARB | Ruijin Hospital | CKD5 Stage Dialysis, Heart Failure | 03/23 | 03/23 | | |
NCT04929600: Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy. |
|
|
| Recruiting | 4 | 120 | RoW | sacubitril/valsartan, Amlodipine | Shanghai Jiao Tong University School of Medicine | Hypertension, Left Ventricular Hypertrophy | 06/23 | 12/23 | | |
NCT04491136: Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM) |
|
|
| Terminated | 4 | 201 | RoW | ACEI/ARB, ARNI, Entresto | Novartis Pharmaceuticals | Heart Failure | 06/23 | 06/23 | | |
NCT05881720: Sacubitril/Valsartan Versus Valsartan in Heart Failure |
|
|
| Completed | 4 | 80 | RoW | Sacubitril / Valsartan Oral Tablet, sacubitril / valsartan (100 mg twice daily), Valsartan 80 mg, Valsartan | Damanhour University, Tanta University | Heart Failure | 06/23 | 06/23 | | |
ChiCTR2100050673: A multicenter randomized controlled trial to evaluate the efficacy and safety of sacubitril/valsartan in CKD 3b-5 non-dialysis patients with mild to moderate hypertension |
|
|
| Recruiting | 4 | 480 | | Sacubitril valsartan + conventional antihypertensive ;Conventional blood pressure reduction program | The Third Affiliated Hospital of Southern Medical University; The Third Affiliated Hospital of Southern Medical University, China Cardiovascular Health Alliance-Nuo Chuang Hypertension Research and Innovation Fund | Chronic kidney disease | | | | |
ChiCTR2300074610: Effect of sacubitril/valsartan on serum potassium levels in auric patients on hemodialysis |
|
|
| Not yet recruiting | 4 | 50 | | None | Peking University Shougang Hospital; Peking University Shougang Hospital, self-financing | End-stage renal disease | | | | |
ChiCTR2100041700: Comparative study of sacubitril valsartan and valsartan in patients of mid-range ejection fraction with ventricular aneurysm after myocardial infarction. |
|
|
| Recruiting | 4 | 300 | | sacubitril valsartan ;valsartan | Xiamen Cardiovascular Hospital, Xiamen University; Xiamen Cardiovascular Hospital, Xiamen University, self-raised | left ventricular aneurysm after myocardial infarction | | | | |
ChiCTR2100050967: A controlled clinical trial of the efficacy and safety of sacubitril/valsartan in reducing urinary protein in patients with low-risk membranous nephropathy |
|
|
| Recruiting | 4 | 100 | | Conventional therapy+sacubitril/valsartan 100mg bid ;Conventional therapy+valsartan 160mg qd | China-Japan Friendship Hospital; China-Japan Friendship Hospital, National key clinical specialty capacity building project | membranous nephropathy | | | | |
ChiCTR2300074600: Application and mechanism of angiotensin receptor-neprilysin inhibitor in early stage of acute myocardial infarction |
|
|
| Recruiting | 4 | 200 | | 50mg Sacubitril/Valsartan twice a day, and the dosage of Sacubitril/Valsartan should be adjusted once every 2 weeks according to the patient's blood pressure.; Valsartan at the same frequency and dose | The First People’s Hospital of Shangqiu; The First People’s Hospital of?Shangqiu, Scientific research funds of the First People's Hospital of Shangqiu City | acute myocardial infarction | | | | |
2022-003046-13: Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent Sakubitryl/walsartan w zapobieganiu uszkodzeniu serca w trakcie leczenia chorych na raka piersi |
|
|
| Ongoing | 4 | 480 | Europe | Entresto, Coated tablet, Entresto 49 mg/51 mg, Entresto 97 mg/103 mg | Śląskie Centrum Chorób Serca, Agencja Badań Medycznych | Heart failure – post-anthracycline cardiomyopathy Niewydolność serca – kardiomiopatia poantracyklinowa, Damage to the heart caused by chemotherapy for breast cancer. Uszkodzenie serca powstałe na skutek chemioterapii nowotworu piersi., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2000034822: Comparing with Enalapril, Efficacy and Safety of Sacubitril /Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction: a Multicenter, Prospective, Non-Randomization, Propensity Score Matched Study |
|
|
| Not yet recruiting | 4 | 858 | | Sacubitril /Valsartan ;enalapril | Chongqing Kanghua Zhonglian Cardiovascular Hospital; Chongqing Kanghua Zhonglian Cardiovascular Hospital, Chongqing Kanghua Zhonglian Cardiovascular Hospital supports related research funds | Heart failure | | | | |
ChiCTR2000035327: Comparison of ARNI and ARB in the treatment of elderly patients with acute decompensated ejection fraction preserved heart failure |
|
|
| Not yet recruiting | 4 | 40 | | ARNI 24/26mg bid;49/51mg bid;97/103mg bid ;ARB 40mg bid;80mg bid;160mg bid | Shanghai General Hospital; Shanghai General Hospital, self-raised | heart failure | | | | |
ChiCTR2000039437: A prospective, multicenter, observational study to assess the efficacy and safety of Sacubitril Valsartan compared with valsartan in patients with acute myocardial infarction |
|
|
| Recruiting | 4 | 2000 | | Sacubatril valsartan, valsartan ;valsartan | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine; Level of the institution：, Self-funded | acute myocardial infarction | | | | |
ChiCTR2200064602: The hemodynamic and neurohumoral mechanisms of ARNI in regulatory cerebral small vessel disease (CSVD) and cognitive impairment progression in hemodialysis patients |
|
|
| Recruiting | 4 | 60 | | ENTRESTO 100mg qd | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Self-finance | Chronic renal failure | | | | |
NCT03938389: The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans |
|
|
| Active, not recruiting | 4 | 90 | US | Sacubitril-Valsartan Tab 97-103 MG, Entresto, Valsartan 160mg, Diovan, Placebo Oral Tablet | Ohio State University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | PreDiabetes, Impaired Glucose Tolerance, Obesity, Blood Pressure | 02/24 | 06/25 | | |
ADIDAS, NCT04707261: Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients |
|
|
| Recruiting | 4 | 1990 | RoW | Dapagliflozin, FORXIGA, Placebo | Xiangtan Central Hospital, Second Xiangya Hospital of Central South University, ZhuZhou Central Hospital | Anemia, Heart Failure | 05/25 | 01/26 | | |
| Completed | 4 | 1 | RoW | electroencephalogram biofeedback, EB, electrical brain stimulation, EBS, ultra-low frequency transcranial magnetic stimulation, ULF-TMS, Sertraline Hydrochloride, SSRI, Clonazepam, Alprazolam, Metoprolol, beta blocker, Olanzapine, Pravastatin Sodium 20 MG, Sacubitril Valsartan Sodium Hydrate, ARNI | Pachankis, Yang I., M.D., First Affiliated Hospital of Chongqing Medical University | COVID-19 Vaccine Adverse Reaction | 03/24 | 03/24 | | |
PREMIER, NCT05164653: Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure |
|
|
| Active, not recruiting | 4 | 400 | Japan | Sacubitril Valsartan Sodium Hydrate, Entresto® Tablets, Novartis Pharma K.K., Standard treatment, Angiotensin Converting Enzyme(ACE) inhibitor or Angiotensin II Receptor Blocker(ARB) etc. | Saga University | Heart Failure | 02/24 | 03/25 | | |
| Recruiting | 4 | 72 | Europe | Heart failure medication, Placebo | University Hospital, Essen | Pre-terminal Cancer | 05/24 | 10/24 | | |
ChiCTR2100054733: Protective effect of Sacubitril/Valsartan on residual renal function in peritoneal dialysis patients: a multicenter, prospective, open label, randomized controlled study |
|
|
| Recruiting | 4 | 200 | | Sacubitril/Valsartan ;Valsartan | the First Affiliated Hospital of Anhui University of Chinese Medicine; the First Affiliated Hospital of Anhui University of Chinese Medicine, Anhui leading talent project of traditional Chinese Medicine | Peritoneal dialysis | | | | |
NCT03738878: Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1 |
|
|
| Active, not recruiting | 4 | 32 | US | Valsartan, LCZ696, Entresto, Bradykinin, Substance P, BNP, Nesiritide, Sitagliptin, Januvia | Vanderbilt University Medical Center | Hypertension | 07/25 | 12/25 | | |
NCT04113109: Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2 |
|
|
| Recruiting | 4 | 80 | US | LCZ 696, Entresto, Icatibant, placebo, Para-aminohippurate, Iohexol | Vanderbilt University Medical Center | Heart Failure | 07/25 | 10/25 | | |
Hyper-Save, NCT06501651: Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy |
|
|
| Not yet recruiting | 4 | 297 | RoW | Sacubitril/Valsartan, Valsartan | Sichuan Academy of Medical Sciences, The Second Affiliated Hospital of Chongqing Medical University, Nanchong Central Hospital, The People's Hospital of Leshan, The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University, Chengdu First people's hospital, Mianyang People's Hospital, Guan'an People's Hospital, Meishan Traditional Chinese Medicine Hospital, Qijiang District People's Hospital, Meishan People's Hospital, The First People's Hospital of Guangyuan, Dazhou Central Hospital | Essential Hypertension, Type 2 Diabetes, Nephropathy | 04/25 | 04/25 | | |
PARACHUTE-HF, NCT04023227: Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC |
|
|
| Active, not recruiting | 4 | 919 | RoW | Sacubitril/valsartan, LCZ696; Entresto; Vymada, Enalapril, Renitec | Novartis Pharmaceuticals | Chagas Disease, Heart Failure | 02/25 | 02/25 | | |
| Recruiting | 4 | 172 | Europe | Sacubitril-valsartan, SGLT2 inhibitor | Universidade do Porto, Faculty of Medicine (FMUP), Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC), Rede de Investigação em Saúde (RISE), Laboratório Associado | Heart Failure With Reduced Ejection Fraction | 11/24 | 02/25 | | |
NCT05528419: Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation |
|
|
| Recruiting | 4 | 300 | RoW | Sacubitril-valsartan, Valsartan | Shanghai Jiao Tong University School of Medicine | Atrial Fibrillation Recurrent, Hypertension | 12/24 | 12/24 | | |
NCT06536309: Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction |
|
|
| Not yet recruiting | 4 | 36 | NA | Sacubitril-valsartan, Entresto, Valsartan, Diovan | Brigham and Women's Hospital | Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis | 12/25 | 09/29 | | |
ChiCTR2100051979: A multicenter, randomized, controlled trial comparing the efficacy and safety of sacubitril valsartan in the prevention of cardiac remodeling in patients with acute myocardial infarction after direct PCI |
|
|
| Not yet recruiting | 4 | 1710 | | Start taking sacubitril valsartan within 2 hours after PCI ;Start taking sacubitril valsartan within 3-7 days after PCI | Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine; Sir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Self-raised | acute myocardial infarction | | | | |
PRESENT-HF, NCT05487261: Pulmonary REsistance Modification Under Treatment With Sacubitril/valsartaN in paTients With Heart Failure With Reduced Ejection Fraction |
|
|
| Recruiting | 4 | 260 | Europe | Sacubitril-valsartan, Enalapril, placebo, Placebo | Clinical Hospital Heliodor Swiecicki of the Medical University of Karol Marcinkowski in Poznań, Medical Research Agency, Poland, Medical University of Bialystok, University of Opole, Medical University of Gdansk, Medical University of Silesia | Heart Failure | 02/25 | 11/25 | | |
ChiCTR2200058161: An observational study on the cardiovascular benefits and safety of sacubitril-valsartan in the treatment of stage 5 chronic kidney disease complicated with refractory hypertension |
|
|
| Not yet recruiting | 4 | | | | The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Other project funding | Chronic kidney disease | | | | |
NCT04649229: Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 |
|
|
| Recruiting | 4 | 80 | US | LCZ 696, Entresto, Placebo, Para-aminohippurate, Iohexol, Aprepitant | Yale University | Heart Failure | 07/25 | 10/25 | | |
ChiCTR2200065148: The effect of Sakobactril / valsartan on vascular elasticity in patients with essential hypertension and early vascular aging: A multicenter clinical trial |
|
|
| Recruiting | 4 | 136 | | sacubitril valsartan; amlodipine besylate tablet | Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Fujian Medical University Union Hospital Medical | essential hypertension and early vascular aging | | | | |
PRAISE-MR, NCT05991284: Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation |
|
|
| Recruiting | 4 | 110 | Europe | Sacubitril-valsartan, Standard of care | Ziekenhuis Oost-Limburg, Jessa Hospital | Heart Failure With Preserved Ejection Fraction, Functional Mitral Regurgitation | 09/25 | 04/26 | | |
ChiCTR2300073598: Comparison of the effects of sacubitril/valsartan and azilsartan on left ventricular remodeling in hypertensive patients with elevated angiopoietin-like 7 based on two-dimensional speckle-tracking echocardiography |
|
|
| Not yet recruiting | 4 | 60 | | Shakubaqu valsartan 200mg/dose, once daily; Azilsartan 20mg/dose, once daily | The First People's Hospital of Lianyungang; The First People's Hospital of Lianyungang, The Lianyungang Health Commission and The First People's Hospital of Lianyungang | hypertension | | | | |
ENAVO-TAVR, NCT05672836: ENAVOgliflozin Outcome Trial in Patients with Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement |
|
|
| Not yet recruiting | 4 | 1040 | RoW | Enavogliflozin, Standard-of-Care, Standard-of-Care medical therapy | Duk-Woo Park, MD, CardioVascular Research Foundation, Korea, Daewoong Pharmaceutical Co. LTD. | Aortic Valve Stenosis, Heart Failure | 12/26 | 04/27 | | |
NCT06035978: Determination of Drug Levels for Pharmacotherapy of Heart Failure |
|
|
| Not yet recruiting | 4 | 100 | RoW | Nebivolol, Nebilet, anatomical-therapeutic-chemical code (ATC) C07AB12, Valsartan and Sacubitril, Entresto, ATC C09DX04, Carvedilol, Dilatrend, ATC C07AG02, Bisoprolol, Concor, ATC C07AB07, Metoprolol, Betaloc ZOK, ATC C07AB02, Spironolactone, Verospiron, ATC C03DA01 | University Hospital Ostrava | Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction | 04/26 | 04/26 | | |
ChiCTR2400088532: A prospective study on the effect of Sacubitril Valsartan Sodium in treatment of type 2 diabetes mellitus complicated with hypertension on insulin resistance |
|
|
| Not yet recruiting | 4 | 120 | | Sacubitril Valsartan therapy; Amlodipine therapy | Armed Police Hospital of Chongqing; Armed Police Hospital of Chongqing, Nan'an District,Chongqing medical scientificresearch project (Joint project of Nan'an District,Chongqing Health Commission and Science and Technology Bureau) | Type 2 diabetes mellitus complicated with hypertension | | | | |
NCT05465031: Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) |
|
|
| Not yet recruiting | 4 | 600 | Europe | Sacubitril-valsartan | Silesian Centre for Heart Diseases, Medical Research Agency | Breast Cancer, Neoplasm, Breast, Breast Diseases, Antihypertensive Agents, Sacubitril/Valsartan, Angiotensin II Type 1 Receptor Blockers, Angiotensin Receptor Antagonists, Molecular Mechanisms of Pharmacological Action, Heart Failure, Cardiac Toxicity, Cancer, Therapy-Related, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity | 12/27 | 02/28 | | |
2016-001124-66: Evaluation of the Entresto effect on sympatic nervous system in patient with heart failure (B2AN-SNS) Etude de l'effet de l'Entresto sur le système nerveux sympathique chez l'insuffisant cardiaque (B2AN-SNS) |
|
|
| Not yet recruiting | 3 | 50 | Europe | Entresto, Coated tablet, Entresto, Not available : ATC group C09 | University Hospital Toulouse, ACCO Association | Heart failure Insuffisance cardiaque, Heart failure Insuffisance cardiaque, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-000220-33: Study to assess the effect of sacubitril/valsartan compared with enalapril on erectile function in patients with heart failure |
|
|
| Not yet recruiting | 3 | 200 | Europe | LCZ696, 50 mg, LCZ696, 100 mg, LCZ696, 200 mg, Enalapril, 2.5 mg, Enalapril, 5 mg, Enalapril, 10 mg, LCZ696, Film-coated tablet, Tablet, Entresto, Enalapril | Novartis Pharma GmbH, Novartis Pharma GmbH | Patients with heart failure with reduced ejection fraction (HFrEF) and erectile dysfunction (ED), Patients with chronic heart failure and erectile dysfunction, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
PERI-STEMI, NCT04912167: The Effects of Sacubitril-Valsartan vs Enalapril on Left Ventricular Remodeling in ST-elevation Myocardial Infarction |
|
|
| Not yet recruiting | 3 | 376 | RoW | Sacubitril-Valsartan, Enalapril, Valsartan | West China Hospital | STEMI | 03/22 | 06/26 | | |
| Recruiting | 3 | 138 | RoW | Sacubitril/valsartan, amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, valsartan | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Resistant Hypertension | 10/22 | 03/23 | | |
2020-005302-26: The effect of sacubitril/valsartan versus ramipril on left ventricular function and remodeling in patients with ischemic heart failure with mid-range ejection fraction Wpływ sakubitrylu/walsartanu w porównaniu z ramiprylem na przebudowę i funkcję lewej komory u pacjentów z niewydolnością serca o etiologii niedokrwiennej i pośredniej frakcji wyrzutowej |
|
|
| Not yet recruiting | 3 | 666 | Europe | Film-coated tablet, Tablet, Entresto 49 mg/51 mg film-coated tablets, Entresto 97 mg/103 mg film-coated tablets, Axtil 2,5 mg, Axtil 5 mg | John Paul II Hospital, Medical Research Agency | heart failure with moderately reduced ejection fraction (HFmrEF) niewydolność serca z pośrednią frakcją wyrzutową, chronic heart failure przewlekła niewydolność serca, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ANSWER-HF, NCT04853758: Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: . |
|
|
| Recruiting | 3 | 200 | RoW | Sacubitril / Valsartan Oral Tablet [Entresto], Angiotensin receptor-neprilisin inhibitor (ARNI), Enalapril, Angiotensin converting enzyme inhibitors (ACE inhibitors) | University of Sao Paulo General Hospital, InCor Heart Institute | Chagas Cardiomyopathy | 12/24 | 12/24 | | |
NCT06149104: A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study |
|
|
| Completed | 3 | 8 | Japan | sacubitril/valsartan | Novartis Pharmaceuticals | Heart Failure | 08/24 | 08/24 | | |
| Completed | 3 | 216 | Europe, Canada, Japan, US, RoW | sacubitril/valsartan, LCZ696 | Novartis Pharmaceuticals | Heart Failure | 12/23 | 12/23 | | |
|
